Hoth Therapeutics expands oncology pipeline with dual patent filings

Hoth Therapeutics (HOTH) announced the filing of two U.S. provisional patent applications that significantly expand the Company’s intellectual property portfolio and establish a new oncology-focused dermatology platform targeting treatment-induced skin toxicity from modern cancer therapies. The first provisional patent application, titled covering the topical treatment of radiation-induced skin toxicity in oncology patients. The second provisional patent application, titled addressing dermatologic toxicities associated with emerging targeted cancer therapies, including second and third menin inhibitors. Together, these dual filings secure priority intellectual property rights around the use of HT-001 to treat dermatologic toxicities across multiple oncology treatment modalities